These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
520 related articles for article (PubMed ID: 28742703)
1. Organ Preservation in cT2N0 Rectal Cancer After Neoadjuvant Chemoradiation Therapy: The Impact of Radiation Therapy Dose-escalation and Consolidation Chemotherapy. Habr-Gama A; São Julião GP; Vailati BB; Sabbaga J; Aguilar PB; Fernandez LM; Araújo SEA; Perez RO Ann Surg; 2019 Jan; 269(1):102-107. PubMed ID: 28742703 [TBL] [Abstract][Full Text] [Related]
2. Is neoadjuvant chemoradiation with dose-escalation and consolidation chemotherapy sufficient to increase surgery-free and distant metastases-free survival in baseline cT3 rectal cancer? São Julião GP; Habr-Gama A; Vailati BB; Aguilar PB; Sabbaga J; Araújo SEA; Mattacheo A; Alexandre FA; Fernandez LM; Gomes DB; Gama-Rodrigues J; Perez RO Eur J Surg Oncol; 2018 Jan; 44(1):93-99. PubMed ID: 29217398 [TBL] [Abstract][Full Text] [Related]
3. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report]. Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308 [No Abstract] [Full Text] [Related]
4. Consolidation chemotherapy during neoadjuvant chemoradiation (CRT) for distal rectal cancer leads to sustained decrease in tumor metabolism when compared to standard CRT regimen. Habr-Gama A; Perez RO; São Julião GP; Proscurshim I; Fernandez LM; Figueiredo MN; Gama-Rodrigues J; Buchpiguel CA Radiat Oncol; 2016 Feb; 11():24. PubMed ID: 26911200 [TBL] [Abstract][Full Text] [Related]
5. Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management? Habr-Gama A; Sabbaga J; Gama-Rodrigues J; São Julião GP; Proscurshim I; Bailão Aguilar P; Nadalin W; Perez RO Dis Colon Rectum; 2013 Oct; 56(10):1109-17. PubMed ID: 24022527 [TBL] [Abstract][Full Text] [Related]
6. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Habr-Gama A; Gama-Rodrigues J; São Julião GP; Proscurshim I; Sabbagh C; Lynn PB; Perez RO Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):822-8. PubMed ID: 24495589 [TBL] [Abstract][Full Text] [Related]
7. [Outcome of watch and wait strategy or organ preservation for rectal cancer following neoadjuvant chemoradiotherapy: report of 35 cases from a single cancer center]. Wu A; Wang L; Du C; Peng Y; Yao Y; Zhao J; Zhan T; Cai Y; Li Y; Sun Y; Ji J Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Apr; 20(4):417-424. PubMed ID: 28440523 [TBL] [Abstract][Full Text] [Related]
8. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE). Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356 [TBL] [Abstract][Full Text] [Related]
9. [Total neoadjuvant therapy followed by watch and wait approach or organ preservation for MRI stratified low-risk rectal cancer: early result from a prospective, single arm trial]. Wang L; Zhao YM; Sun TT; Xu YL; Li SJ; Zhang XY; Cai Y; Li YH; Li ZW; Chen PJ; Peng YF; Wang WH; Wu AW Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):258-265. PubMed ID: 32192305 [No Abstract] [Full Text] [Related]
10. [Long-term prognostic analysis on complete/near-complete clinical remission for mid-low rectal cancer after neoadjuvant chemoradiotherapy]. Wang L; Li S; Zhang X; Sun T; Du C; Chen N; Peng Y; Yao Y; Zhan T; Zhao J; Cai Y; Li Y; Wang W; Li Z; Sun Y; Ji J; Wu A Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1240-1248. PubMed ID: 30506534 [TBL] [Abstract][Full Text] [Related]
11. ["Watch and wait" strategy after neoadjuvant therapy for rectal cancer: status survey of perceptions, attitudes and treatment selection in Chinese surgeons]. Sun TT; Wang L; Yao YF; Peng YF; Zhao J; Zhan TC; Leng JH; Wang HY; Chen N; Chen PJ; Li YJ; Zhang X; Liu XZ; Zhang Y; Wu AW Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):550-559. PubMed ID: 31238634 [No Abstract] [Full Text] [Related]
12. Brazil-TNT: A Randomized Phase 2 Trial of Neoadjuvant Chemoradiation Followed by FOLFIRINOX Versus Chemoradiation for Stage II/III Rectal Cancer. Bugano DDG; Santos VM; Campos-Bragagnoli A; Melo JCM; Romagnolo LGC; Barbosa Neto O; Carvalho IT; Karassawa-Helito J; Ortega CD; Tridente CF; Gerbasi LS; Tustumi F; Giovani Blasi PB; Novaes Figueiredo de Araujo M; Pandini RV; Seid VE; Portilho AS; Buosso A; Rolla F; Schettino GPP; Araujo SEA Clin Colorectal Cancer; 2024 Sep; 23(3):238-244. PubMed ID: 38851990 [TBL] [Abstract][Full Text] [Related]
13. Transanal local excision for distal rectal cancer and incomplete response to neoadjuvant chemoradiation - does baseline staging matter? Perez RO; Habr-Gama A; São Julião GP; Proscurshim I; Coelho AQ; Figueiredo MN; Fernandez LM; Gama-Rodrigues J Dis Colon Rectum; 2014 Nov; 57(11):1253-9. PubMed ID: 25285691 [TBL] [Abstract][Full Text] [Related]
14. Intentional Watch and Wait or Organ Preservation Surgery Following Neoadjuvant Chemoradiotherapy Plus Consolidation CAPEOX for MRI-defined Low-risk Rectal Cancer: Findings From a Prospective Phase 2 Trial (PKUCH-R01 Trial, NCT02860234). Wang L; Zhang XY; Zhao YM; Li SJ; Li ZW; Sun YS; Wang WH; Wu AW; Ann Surg; 2023 Apr; 277(4):647-654. PubMed ID: 35766394 [TBL] [Abstract][Full Text] [Related]
15. Long-term Outcome of an Organ Preservation Program After Neoadjuvant Treatment for Rectal Cancer. Martens MH; Maas M; Heijnen LA; Lambregts DM; Leijtens JW; Stassen LP; Breukink SO; Hoff C; Belgers EJ; Melenhorst J; Jansen R; Buijsen J; Hoofwijk TG; Beets-Tan RG; Beets GL J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27509881 [TBL] [Abstract][Full Text] [Related]
16. Planned organ preservation for early T2-3 rectal adenocarcinoma: A French, multicentre study. Gérard JP; Barbet N; Gal J; Dejean C; Evesque L; Doyen J; Coquard R; Gugenheim J; Benizri E; Schiappa R; Baudin G; Benezery K; François E Eur J Cancer; 2019 Feb; 108():1-16. PubMed ID: 30580125 [TBL] [Abstract][Full Text] [Related]
17. Impact of Organ-Preserving Strategies on Anorectal Function in Patients with Distal Rectal Cancer Following Neoadjuvant Chemoradiation. Habr-Gama A; Lynn PB; Jorge JM; São Julião GP; Proscurshim I; Gama-Rodrigues J; Fernandez LM; Perez RO Dis Colon Rectum; 2016 Apr; 59(4):264-9. PubMed ID: 26953984 [TBL] [Abstract][Full Text] [Related]
18. Organ preservation with local excision or active surveillance following chemoradiotherapy for rectal cancer. Creavin B; Ryan E; Martin ST; Hanly A; O'Connell PR; Sheahan K; Winter DC Br J Cancer; 2017 Jan; 116(2):169-174. PubMed ID: 27997526 [TBL] [Abstract][Full Text] [Related]
19. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. Garcia-Aguilar J; Renfro LA; Chow OS; Shi Q; Carrero XW; Lynn PB; Thomas CR; Chan E; Cataldo PA; Marcet JE; Medich DS; Johnson CS; Oommen SC; Wolff BG; Pigazzi A; McNevin SM; Pons RK; Bleday R Lancet Oncol; 2015 Nov; 16(15):1537-1546. PubMed ID: 26474521 [TBL] [Abstract][Full Text] [Related]
20. Nonoperative management after neoadjuvant therapy for rectal cancer: A single institution experience over 5 years. Strode M; Shah R; Boland PM; Francescutti VA; Mangieri CW; Attwood K; Nurkin SJ Surg Oncol; 2019 Mar; 28():116-120. PubMed ID: 30851884 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]